Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

Amir T. Fathi, Mark J. Levis, Daniela Hernandez et al.|Cancer|2017

Cited by 31